Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?

Kapustin, Roman V.; Kascheeva, T. K.; Alekseenkova, Elena N.; Shelaeva, Elizaveta V.

doi:10.1080/14767058.2020.1743658

Cited by 7 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitamin D deficiency was more common in T1DM groups in both studies but the predictive potential of vitamin D differed. The ORs were non-significant for the active form of vitamin D, 25(OH)D, in Vestgaard et al (2017b) similar to Kapustin et al (2020) However, Kapustin et al (2020) were able to show significantly elevated levels of the precursor form of vitamin D, 1,25(OH) 2 D, and its ratio with vitamin D binding protein (VDBP) in second and third trimesters in PE groups. Every unit increase in 1,25(OH) 2 D:VDBP was correlated with OR = 2.71 in the second trimester and OR = 2.53 in the third trimester for later PE development.…”

Section: Resultsmentioning

confidence: 89%

“…In the same study, sFlt-1, PlGF and sFlt-1/PlGF ratios were only predictive from the third trimester ( Kelly et al, 2019 ). PAPP-A was found to be not different between groups of women with T1DM who developed PE or remained normotensive ( Kapustin et al, 2020 ).…”

Section: Resultsmentioning

confidence: 95%

“…A detailed summary of study and cohort characteristics can be found in Table 2 . Of the 18 studies selected for the current review, three were systematic reviews ( Vestgaard et al, 2017a ; Cavero-Redondo et al, 2018 ; Xiang et al, 2018 ), six were case-control studies ( Basu et al, 2015 ; Tsiakkas et al, 2015 ; Gutaj et al, 2017 ; Kelly et al, 2017 ; Kelly et al, 2018 ; Kelly et al, 2020 ) and nine were cohort studies ( Maresh et al, 2015 ; Wotherspoon et al, 2016b ; Klemetti et al, 2016 ; Lauszus and Fuglsang, 2016 ; Vestgaard et al, 2017b ; Nielsen et al, 2018 ; Kelly et al, 2019 ; Perea et al, 2019 ; Kapustin et al, 2020 ). The number of women with T1DM in the cohorts ranged from 47 to 1,094, with Vestgaard et al and Xiang et al having pooled 11,518 and 3,239 participants with T1DM, respectively ( Vestgaard et al, 2017a ; Xiang et al, 2018 ).…”

Section: Resultsmentioning

confidence: 99%

“…PE prevalence within cohorts ranged from 4.8% to 35.9%. There was heterogeneity in the timeframe of biomarker measurements, with 12 studies ( Basu et al, 2015 ; Tsiakkas et al, 2015 ; Klemetti et al, 2016 ; Lauszus and Fuglsang, 2016 ; Gutaj et al, 2017 ; Kelly et al, 2017 ; Cavero-Redondo et al, 2018 ; Kelly et al, 2018 ; Nielsen et al, 2018 ; Kelly et al, 2019 ; Perea et al, 2019 ; Kelly et al, 2020 ) recording biomarker levels across all three trimesters of pregnancy, four studies ( Maresh et al, 2015 ; Wotherspoon et al, 2016b ; Vestgaard et al, 2017a ; Vestgaard et al, 2017b ) in any two trimesters and one study ( Kapustin et al, 2020 ) taking measurements in the first trimester only. The timing of biomarker measurements was not specified in Xiang et al (2018) .…”

Section: Resultsmentioning

confidence: 99%

“…Nine studies ( Basu et al, 2015 ; Tsiakkas et al, 2015 ; Lauszus and Fuglsang, 2016 ; Vestgaard et al, 2017b ; Kelly et al, 2018 ; Nielsen et al, 2018 ; Kelly et al, 2019 ; Kapustin et al, 2020 ; Kelly et al, 2020 ) examined other circulating molecules. Two studies ( Tsiakkas et al, 2015 ; Kelly et al, 2019 ) investigated angiogenic factors soluble Fms-like tyrosine kinase 1 (sFlt-1), soluble endoglin (sEng) and placental growth factor (PlGF) in PE prediction among women with T1DM.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Pre-Eclampsia Biomarkers for Women With Type 1 Diabetes Mellitus: A Comprehensive Review of Recent Literature

Freimane

Kerrigan

Eastwood

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Background: Pre-eclampsia is a serious consideration for women with type 1 diabetes mellitus (T1DM) planning pregnancy. Risk stratification strategies, such as biomarkers measured in the first trimester of pregnancy, could help identify high-risk women. The literature on T1DM-specific pre-eclampsia biomarkers is expanding. We aimed to provide a narrative review of recently published evidence to identify the most promising biomarker candidates that could be targeted for clinical implementation in existing PE models.Methods: A search using MeSH terms was carried out of Medline, EMBASE, Maternity and Infant Care, Web of Science, and Scopus for relevant papers published since 2015 inclusive and in English. The time limit was applied from the publication of the preceding systematic review in this field. Included studies had pre-eclampsia as a primary outcome, measured one or more serum, plasma or urine biomarkers at any time during pregnancy, and had a distinct group of women with T1DM who developed pre-eclampsia. Studies with pre-eclampsia as a composite outcome were not considered. No restrictions on study types were applied. A narrative synthesis approach was adopted for analysis.Results: A total of 510 records were screened yielding 18 eligible studies relating to 32 different biomarkers. Higher first-trimester levels of HbA1c and urinary albumin were associated with an increased risk of pre-eclampsia development in women with T1DM. Urinary neutrophil gelatinase-associated lipocalin and adipokines were novel biomarkers showing moderate predictive ability before 15 gestational weeks. Two T1DM-specific pre-eclampsia prediction models were proposed, measuring adipokines or urinary neutrophil gelatinase-associated lipocalin together with easily attainable maternal clinical characteristics. Contradicting previous literature, pre-eclampsia risk in women with T1DM was correlated with vitamin D levels and atherogenic lipid profile in the context of haptoglobin phenotype 2-2. Pregnancy-associated plasma protein-A and soluble endoglin did not predict pre-eclampsia in women with T1DM, and soluble Fms-like tyrosine kinase 1 only predicted pre-eclampsia from the third trimester.Conclusion: Maternally derived biomarkers reflecting glycemic control, insulin resistance and renal dysfunction performed better as PE predictors among women with T1DM than those derived from the placenta. These biomarkers could be trialed in current PE prediction algorithms to tailor them for women with T1DM.

show abstract

Section: Resultsmentioning

confidence: 89%

Section: Resultsmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Pre-Eclampsia Biomarkers for Women With Type 1 Diabetes Mellitus: A Comprehensive Review of Recent Literature

Freimane

Kerrigan

Eastwood

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

Fetal growth regulation via insulin-like growth factor axis in normal and diabetic pregnancy

Alekseenkova

Selkov

Kapustin

2022

Journal of Perinatal Medicine

View full text Add to dashboard Cite

Objectives Diabetes mellitus (DM) in pregnancy and gestational diabetes remain a considerable cause of pregnancy complications, and fetal macrosomia is among them. Insulin, insulin-like growth factors (IGFs), and components of their signal-transduction axes belong to the predominant growth regulators and are implicated in glucose homeostasis. This study aimed to evaluate the available evidence on the association between the IGF axis and fetal anthropometric parameters in human diabetic pregnancy. Methods PubMed, Medline, Web of Science, and CNKI databases (1981–2021) were searched. Results Maternal and cord serum IGF-I levels are suggested to be positively associated with weight and length of neonates born to mothers with type 1 DM. The results concerning IGF-II and IGFBPs in type 1 DM or any of the IGF axis components in type 2 DM remain controversial. The alterations of maternal serum IGFs concentrations throughout diabetic and non-diabetic pregnancy do not appear to be the same. Maternal 1st trimester IGF-I level is positively associated with fetal birth weight in DM. Conclusions Research on the IGF axis should take gestational age of sampling, presence of DM, and insulin administration into account. Maternal 1st trimester IGF-I level might become a predictor for macrosomia development in diabetic pregnancy.

show abstract

Analysis of the Effectiveness of First Trimester Nucal Translucence, Free Beta-Human Chorionic Gonadotropin, and Pregnancy-Related Plasma Protein-A in Prediction of Pregnancy Complications

SUMAN

BÜTÜN

BÜYÜK

et al. 2022

Black Sea Journal of Health Science

View full text Add to dashboard Cite

Abstract Objective:In this study, we aimed to investigate whether there is a relationship between NT and serum markers PAPP-A and β-hCG values measured in the first-trimester screening test, and birth weight and hypertension. Keywords: First trimester NT,PAPP-A, β-hCG, birthweight, preeclampsia Materials-Methods:454 pregnant women who underwent the first trimester Down syndrome screening test were included in the study. All the measurements and values of NT, PAPP-A, and β-hCG levels were done between the weeks of 11-14 pregnancies. The values of PAPP-A and β-hCG converted to multiples of the corrected median (MoM) were determined with the PRISCA software package. Results:In terms of predicting SGA infants, when PAPP-A value was

show abstract

Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?

Cited by 7 publications

References 38 publications

Pre-Eclampsia Biomarkers for Women With Type 1 Diabetes Mellitus: A Comprehensive Review of Recent Literature

Pre-Eclampsia Biomarkers for Women With Type 1 Diabetes Mellitus: A Comprehensive Review of Recent Literature

Fetal growth regulation via insulin-like growth factor axis in normal and diabetic pregnancy

Analysis of the Effectiveness of First Trimester Nucal Translucence, Free Beta-Human Chorionic Gonadotropin, and Pregnancy-Related Plasma Protein-A in Prediction of Pregnancy Complications

Contact Info

Product

Resources

About